CVS Group plc (CVSG), the UK and Australia-focused veterinary services provider, has disclosed the purchase of 70,000 of its own ordinary shares between 9 and 13 November 2026 as part of its ongoing share buyback programme. The shares were acquired through Joh. Berenberg, Gossler & Co. KG, London Branch, at prices ranging from 1,354p to 1,417p, with a volume weighted average price of 1,385.89p. The company intends to cancel all purchased shares, reducing the total shares in issue to 66,525,634. Since the programme launched on 26 May 2026, CVS has repurchased 3,637,465 ordinary shares in aggregate at a weighted average price of 1,256.5 pence per share.

Key Points

  • CVS Group plc (CVSG), listed on the Main Market of the London Stock Exchange
  • 70,000 ordinary shares repurchased between 9 and 13 November 2026 via Berenberg and earmarked for cancellation
  • Volume weighted average price of 1,385.89p; programme total of 3,637,465 shares at a weighted average of 1,256.5p since 26 May 2026
  • Investors should watch the pace of further buyback tranches and any updated capital allocation guidance from management

CVS Group Buys Back 70,000 Shares Between 9–13 November 2026 via Berenberg

CVS Group executed the latest tranche of its share buyback programme during the week of 9 to 13 November 2026, purchasing 70,000 ordinary shares of 0.2 pence each through appointed broker Joh. Berenberg, Gossler & Co. KG, London Branch. The lowest price paid per share was 1,354.00p and the highest was 1,417.00p, producing a volume weighted average price of 1,385.89p. The announcement states that CVS intends to cancel all of the purchased shares rather than hold them in treasury, a step that mechanically reduces the company's total share count and can enhance earnings per share over time.

Shares in Issue Fall to 66,525,634 Following Cancellation of Latest Buyback Tranche

Following settlement and cancellation of the 70,000 shares, CVS will have 66,525,634 ordinary shares in issue, with no shares held in treasury. This figure also represents the total number of voting rights in the company and serves as the reference denominator shareholders must use when calculating whether their interests trigger disclosure obligations under the Financial Conduct Authority's Disclosure and Transparency Rules. The company's disclosure is made in compliance with Article 5(1)(b) of the UK-retained version of the Market Abuse Regulation, with a full breakdown of individual trades published via the London Stock Exchange's RNS service.

Programme-to-Date: 3,637,465 Shares Repurchased at a Weighted Average of 1,256.5p Since May 2026

Since the Share Buyback Programme commenced on 26 May 2026, CVS has repurchased a cumulative total of 3,637,465 ordinary shares at a weighted average price of 1,256.5 pence per share. The latest weekly tranche was executed at a notably higher average than the programme-to-date figure, reflecting the price at which shares traded during that period. CVS Group operates over 475 veterinary practices across the UK and Australia, employing 9,000 personnel including 2,500 veterinary surgeons, and also runs diagnostic laboratories and the Animed Direct online retail business alongside its core practices division.